Interestingly, our study demonstrates that Hamp1 also had an impact on erythropoietin, erythroferrone and hemoglobin expressions, both in the spleen and head kidney, with very significant decreases in the earlier days post administration, coinciding with the early development of anemia, and a later recovery and even over expression, matching the gradual recovery from anemia. The gene discussed is EPO; the disease is anemia (phenotype).